| PMID,Cancer Type,Antibody Immunotherapy Agents,Total Numebr of Participants,immune-related adverse event grades,Univariate or Multivariate Model,retrospective or prospective cohort |
| 26222619,multiple cancer types,pembrolizumab,83,1–3,multivariate,retrospective cohort |
| 26446948,Melanoma,nivolumab,143,1–3,multivariate,retrospective cohort |
| 28975219,non-small-cell lung carcinoma,nivolumab,130,1–4,multivariate,retrospective cohort |
| 29296533,non-small-cell lung carcinoma,nivolumab/pembrolizumab,58,1–2,multivariate,retrospective cohort |
| 28652280,multiple cancer types,nivolumab/pembrolizumab,173,1–2,multivariate,retrospective cohort |
| 27998967,non-small-cell lung carcinoma,pembrolizumab,48,1–3,univariate,prospective cohort |
| 27510892,Melanoma,nivolumab,35,1–2,univariate,retrospective cohort |
| 30442524,non-small-cell lung carcinoma,nivolumab/pembrolizumab,270,1–4,univariate,retrospective cohort |
| 30589930,non-small-cell lung carcinoma,nivolumab/pembrolizumab,137,1–4,univariate,retrospective cohort |
| 29290265,non-small-cell lung carcinoma,nivolumab,18,1–4,univariate,retrospective cohort |
| 30682533,multiple cancer types,nivolumab/pembrolizumab,106,1–4,multivariate,retrospective cohort |
| 30506406,non-small-cell lung carcinoma,nivolumab,195,1–4,multivariate,retrospective cohort |
| 30506406,non-small-cell lung carcinoma,nivolumab/pembrolizumab,246,1–2,multivariate,retrospective cohort |
| 29975414,Melanoma,ipilimumab,281,N.A.,univariate,retrospective cohort |
| 30539281,Melanoma,nivolumab/pembrolizumab,173,1–5,multivariate,retrospective cohort |
| 30311424,non-small-cell lung carcinoma,nivolumab,104,1–4,multivariate,retrospective cohort |
| 30197259,non-small-cell lung carcinoma,nivolumab/pembrolizumab/atezolizumab,91,1–4,univariate,retrospective cohort |
| 29382669,non-small-cell lung carcinoma,pembrolizumab,97,1–4,multivariate,retrospective cohort |
| 29656747,non-small-cell lung carcinoma,nivolumab,613,≥3,multivariate,retrospective cohort |
| 30528047,Melanoma,nivolumab,15,1–2,multivariate,retrospective cohort |
| 30782080,multiple cancer types,nivolumab/pembrolizumab,103,1–4,univariate,retrospective cohort |
| 30885550,non-small-cell lung carcinoma,nivolumab/pembrolizumab,559,1–4,multivariate,retrospective cohort |
| 30911841,non-small-cell lung carcinoma,nivolumab/pembrolizumab,133,1–4,multivariate,retrospective cohort |
| 31021392,non-small-cell lung carcinoma,nivolumab/pembrolizumab,83,N.A.,univariate,prospective cohort |
| 30944023,renal cell carcinoma,nivolumab,389,1–4,multivariate,retrospective cohort |
| 31086392,multiple cancer types,nivolumab,191,N.A.,univariate,retrospective cohort |
| 31081424,non-small-cell lung carcinoma,nivolumab/pembrolizumab,112,3–4,univariate,retrospective cohort |
| 30935847,renal cell carcinoma,nivolumab,47,1–4,multivariate,retrospective cohort |
| 30425107,Melanoma,ipilimumab,133,1–4,univariate,retrospective cohort |
| 31088239,Melanoma,ipilimumab,100,1–3,univariate,retrospective cohort |
|
|
